Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 3/2012

01.03.2012 | Original article

Design of immunogenic and effective multi-epitope DNA vaccines for melanoma

verfasst von: Hyun-Il Cho, Esteban Celis

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Plasmid DNA vaccination is an attractive way to elicit T cell responses against infectious agents and tumor cells. DNA constructs can be designed to contain multiple T cell epitopes to generate a diverse immune response to incorporate numerous antigens and to reduce limitations due to MHC restriction into a single entity. We have prepared cDNA plasmid constructs containing several mouse T cell epitopes connected by either furin-sensitive or furin-resistant linkers and studied the effects of a cationic cell-penetrating sequence from HIV-tat. Significant CD8 T cell responses were obtained with multi-epitope DNA vaccines followed by in vivo electroporation regardless of the type of linker used and whether the construct had the HIV-tat sequence. The magnitude of immune responses was very similar to all CD8 T cell epitopes contained within each vaccine construct, indicating the absence of immunodominance. Incorporating a T helper epitope into the constructs increased the T cell responses. Prophylactic and therapeutic antitumor responses against B16 melanoma were obtained using a construct containing epitopes from melanosomal proteins, indicating that this vaccination was successful in generating responses to self-antigens that potentially may be subjected to immune tolerance. These findings are useful for designing DNA vaccines for a multitude of diseases where T lymphocytes play a protective or therapeutic role.
Literatur
1.
Zurück zum Zitat Bijker MS, Melief CJ, Offringa R, van der Burg SH (2007) Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 6(4):591–603PubMedCrossRef Bijker MS, Melief CJ, Offringa R, van der Burg SH (2007) Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 6(4):591–603PubMedCrossRef
2.
Zurück zum Zitat Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6(5):404–414PubMedCrossRef Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6(5):404–414PubMedCrossRef
3.
Zurück zum Zitat De Groot AS (2006) Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov Today 11(5–6):203–209PubMedCrossRef De Groot AS (2006) Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov Today 11(5–6):203–209PubMedCrossRef
4.
Zurück zum Zitat Cho HI, Celis E (2009) Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 69(23):9012–9019PubMedCrossRef Cho HI, Celis E (2009) Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 69(23):9012–9019PubMedCrossRef
5.
Zurück zum Zitat Assudani D, Cho HI, DeVito N, Bradley N, Celis E (2008) In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res 68(23):9892–9899PubMedCrossRef Assudani D, Cho HI, DeVito N, Bradley N, Celis E (2008) In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res 68(23):9892–9899PubMedCrossRef
6.
Zurück zum Zitat Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E (2007) Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 67(3):1326–1334PubMedCrossRef Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E (2007) Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 67(3):1326–1334PubMedCrossRef
7.
Zurück zum Zitat Davila E, Kennedy R, Celis E (2003) Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 63(12):3281–3288PubMed Davila E, Kennedy R, Celis E (2003) Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 63(12):3281–3288PubMed
8.
Zurück zum Zitat Itoh T, Celis E (2005) Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother 28(5):430–437PubMedCrossRef Itoh T, Celis E (2005) Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother 28(5):430–437PubMedCrossRef
9.
Zurück zum Zitat Lu J, Higashimoto Y, Appella E, Celis E (2004) Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immuno 172(7):4575–4582 Lu J, Higashimoto Y, Appella E, Celis E (2004) Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immuno 172(7):4575–4582
10.
Zurück zum Zitat Lu J, Wettstein PJ, Higashimoto Y, Appella E, Celis E (2001) TAP-independent presentation of CTL epitopes by Trojan antigens. J Immuno 166(12):7063–7071 Lu J, Wettstein PJ, Higashimoto Y, Appella E, Celis E (2001) TAP-independent presentation of CTL epitopes by Trojan antigens. J Immuno 166(12):7063–7071
11.
Zurück zum Zitat Cho HI, Lee YR, Celis E (2011) Interferon gamma limits the effectiveness of melanoma peptide vaccines. Blood 117:135–144PubMedCrossRef Cho HI, Lee YR, Celis E (2011) Interferon gamma limits the effectiveness of melanoma peptide vaccines. Blood 117:135–144PubMedCrossRef
12.
Zurück zum Zitat Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, Delaere P, Branellec D, Schwartz B, Scherman D (1999) High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 96(8):4262–4267PubMedCrossRef Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, Delaere P, Branellec D, Schwartz B, Scherman D (1999) High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 96(8):4262–4267PubMedCrossRef
13.
Zurück zum Zitat Aihara H, Miyazaki J (1998) Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16(9):867–870PubMedCrossRef Aihara H, Miyazaki J (1998) Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16(9):867–870PubMedCrossRef
14.
Zurück zum Zitat Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J (2005) Electroporation as a “prime/boost” strategy for naked DNA vaccination against a tumor antigen. J Immuno 174(10):6292–6298 Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J (2005) Electroporation as a “prime/boost” strategy for naked DNA vaccination against a tumor antigen. J Immuno 174(10):6292–6298
15.
Zurück zum Zitat Gronevik E, Mathiesen I, Lomo T (2005) Early events of electroporation-mediated intramuscular DNA vaccination potentiate Th1-directed immune responses. J Gene Med 7(9):1246–1254PubMedCrossRef Gronevik E, Mathiesen I, Lomo T (2005) Early events of electroporation-mediated intramuscular DNA vaccination potentiate Th1-directed immune responses. J Gene Med 7(9):1246–1254PubMedCrossRef
18.
Zurück zum Zitat Doan T, Herd K, Ramshaw I, Thomson S, Tindle RW (2005) A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour. Cancer Immunol Immunother 54(2):157–171PubMedCrossRef Doan T, Herd K, Ramshaw I, Thomson S, Tindle RW (2005) A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour. Cancer Immunol Immunother 54(2):157–171PubMedCrossRef
19.
Zurück zum Zitat Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast WM (2001) Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 166(9):5366–5373PubMed Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast WM (2001) Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 166(9):5366–5373PubMed
20.
Zurück zum Zitat Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A (2001) Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19(32):4652–4660PubMedCrossRef Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A (2001) Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19(32):4652–4660PubMedCrossRef
21.
Zurück zum Zitat Hanke T, Neumann VC, Blanchard TJ, Sweeney P, Hill AV, Smith GL, McMichael A (1999) Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 17(6):589–596PubMedCrossRef Hanke T, Neumann VC, Blanchard TJ, Sweeney P, Hill AV, Smith GL, McMichael A (1999) Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 17(6):589–596PubMedCrossRef
22.
Zurück zum Zitat Kotturi MF, Scott I, Wolfe T, Peters B, Sidney J, Cheroutre H, von Herrath MG, Buchmeier MJ, Grey H, Sette A (2008) Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol 181(3):2124–2133PubMed Kotturi MF, Scott I, Wolfe T, Peters B, Sidney J, Cheroutre H, von Herrath MG, Buchmeier MJ, Grey H, Sette A (2008) Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol 181(3):2124–2133PubMed
23.
Zurück zum Zitat Tenzer S, Wee E, Burgevin A, Stewart-Jones G, Friis L, Lamberth K, Chang CH, Harndahl M, Weimershaus M, Gerstoft J, Akkad N, Klenerman P, Fugger L, Jones EY, McMichael AJ, Buus S, Schild H, van Endert P, Iversen AK (2009) Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol 10(6):636–646PubMedCrossRef Tenzer S, Wee E, Burgevin A, Stewart-Jones G, Friis L, Lamberth K, Chang CH, Harndahl M, Weimershaus M, Gerstoft J, Akkad N, Klenerman P, Fugger L, Jones EY, McMichael AJ, Buus S, Schild H, van Endert P, Iversen AK (2009) Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol 10(6):636–646PubMedCrossRef
Metadaten
Titel
Design of immunogenic and effective multi-epitope DNA vaccines for melanoma
verfasst von
Hyun-Il Cho
Esteban Celis
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 3/2012
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1110-7

Weitere Artikel der Ausgabe 3/2012

Cancer Immunology, Immunotherapy 3/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.